2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2891

Prognostic Significance of Autoantibody Positivity in Interstitial Lung Disease: A Retrospective Case-Control Study
Abstract Number: 2827

Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death
Abstract Number: 2925

Programmed Cell Death (PD)-1 May Play a Significant Role in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 846

Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: Using Speckle Tracking Strain Echocardiography to Identify Patients at Risk
Abstract Number: 2362

Progression of Pain and Ultrasound Detected Synovitis in Patients with Erosive Hand Osteoarthritis over One Year
Abstract Number: 1717

Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Abstract Number: 1497

Progressive Decline of Lung Function in Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: 1184

Projected 2015 Prevalence of Physician-Diagnosed Primary SjöGren’s Syndrome Based on 1976-2005 Annual Incidence Rates in a Well-Defined U.S. Population
Abstract Number: 539

Promis Short Forms Are Relevant to People Living with RA: Results of Cognitive Debriefing Interviews
Abstract Number: 1154

Promoting Self-Management Techniques for Osteoarthritis Pain: a Pilot Study of Nurse Practitioner Led Coping Skills Training
Abstract Number: 213

Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Abstract Number: 2861

Proportions of Circulating Follicular Helper T Cells and Complement Levels, White Blood Cell Counts, and Skin Manifestations in Patients with Active Systemic Lupus Erythematosus
Abstract Number: 415

Proposal for a Damage Index for Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)
Abstract Number: 414

Proposal for the Definition of Inactivity of Juvenile Idiopathic Arthritis Related Uveitis from the Multinational Interdisciplinary Working Group for Uveitis in Childhood Group (MIWGUC)
Abstract Number: 2390

Proposal of Assessment of the Activity of Juvenile Localised Scleroderma. Results of the Consensus Meeting in Hamburg, Germany December 2015

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].